Avicenna J Med Biotech arij002 Avicenna Journal of Medical Biotechnology 2008-2835 2008-4625 Avicenna Research Institute ajmb30423 Pasteurella multocida Vaccine Candidates: A Systematic Review MostaanSaiedGhasemzadehAbbasSardariSoroushDepartment of Pathobiology, Faculty of Public Health, Tehran University of Medical Sciences , Tehran, IranShokrgozarMohammad AliMycobacteriology Research Center, National Research Institute of Tuberculosis and Lung Disease (NRITLD), Shahid Beheshti University of Medical Sciences , Tehran, IranNikbakht BrujeniGholamrezaAbolhassaniMohsenEhsaniParastooDepartment of Molecular Biotechnology, Cell Sciences Research Center, Royan Institute for Biotechnology, ACECR, Isfahan, IranAsadi KaramMohammad Reza 12 3 140 147 22 1 2020 16 3 2020

<p><em>Pasteurella multocida (P.&nbsp;multocida)</em> is the highly contagious causative agent of a broad range of diseases in animals as well as an occasional human pathogen. Economically significant infections caused by <em>P.&nbsp;multocida</em> include avian fowl cholera, rabbit snuffles, and hemorrhagic septicemia in cattle, goats and pigs. Chemotherapy of pasteurellosis infections has some limitations, such as high cost of treatment, low efficacy, and the possibility of therapy failure due to antibiotic resistance. Prophylactic immunization offers a safe and effective preventive measure in case of zoonotic diseases. Bacterins, live attenuated and some old traditional vaccines against pasteurellosis remain in use today, beside their limitations. However, the past few years have seen significant progress in research to identify modern, effective vaccine candidates, but there is no new vaccine produced by new strategies. While scientists should struggle with a lot of aspects to design vaccine producing strategies, this review shows how pasteurellosis vaccine evolved and the limitations in its application which need to be overcome.&nbsp;</p>